Mostrando 8 resultados de: 8
Filtros aplicados
Publisher
CNS and Neurological Disorders - Drug Targets(1)
Journal of Alzheimer's Disease(1)
Journal of Nanobiotechnology(1)
Molecular Neurobiology(1)
Nanomedicine: Nanotechnology, Biology, and Medicine(1)
Área temáticas
Enfermedades(8)
Farmacología y terapéutica(6)
Medicina y salud(4)
Fisiología humana(3)
Ginecología, obstetricia, pediatría, geriatría(2)
Origen
scopus(8)
Comparative study of Ex Vivo transmucosal permeation of pioglitazone nanoparticles for the treatment of Alzheimer's disease
ArticleAbstract: Pioglitazone has been reported in the literature to have a substantial role in the improvement of ovPalabras claves:Alzheimer's disease, Nanoparticles, Pioglitazone, PLGA-PEG, Transmucosal permeationsAutores:Calpena A.C., Espina M., García M.L., Halbaut L., Lupe Carolina Espinoza, Silva-Abreu M.Fuentes:scopusDevelopment of a nasal donepezil-loaded microemulsion for the treatment of Alzheimer’s disease: In vitro and Ex vivo characterization
ArticleAbstract: Background: Donepezil (DPZ) is widely prescribed as a specific and reversible acetylcholinesterase iPalabras claves:Alzheimer’s disease, Delivery systems, Donepezil, Intranasal route, Microemulsion, permeationAutores:Calpena A.C., Clares-Naveros B., Fábrega M.J., García M.L., Lupe Carolina Espinoza, Vacacela M.Fuentes:scopusEpigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy
ArticleAbstract: Temporal lobe epilepsy is the most common type of pharmacoresistant epilepsy in adults. EpigallocatePalabras claves:Epigallocatechin-3-gallate, Epilepsy, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Calpena A.C., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Sanchez-Lopez E.Fuentes:scopusMemantine for the treatment of dementia: A review on its current and future applications
ReviewAbstract: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the presence in the brainPalabras claves:Alzheimer's disease, Amyloid-protein, Extrasynaptic N-Methyl-D-aspartate receptor, Memantine, Tau proteinAutores:Antoni Camins, Auladell C., Busquets O., Casadesús G., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Olloquequi J., Pelegrí Gabalda C., Sanchez-Lopez E., Verdaguer E., Vilaplana J., Zárate C.B.Fuentes:scopusMemantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: In vitro and in vivo characterization
ArticleAbstract: Background: Memantine, drug approved for moderate to severe Alzheimer's disease, has not shown to bePalabras claves:Alzheimer's disease, APPswe/PS1dE9 mice, astrocytes, BEnd.3, Brain targeting, Memantine, Nanoparticles, β-Amyloid plaquesAutores:Antoni Camins, Calpena A.C., Cano A., Carmona N., Egea M.A., Espina M., Ettcheto M., García M.L., Sanchez-Lopez E., Silva A.M., Souto E.M.B.Fuentes:scopusMemantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma
ArticleAbstract: Glaucoma is a multifactorial neurodegenerative disease associated with retinal ganglion cells (RGC)Palabras claves:drug delivery, glaucoma, Memantine, Nanoparticles, PLGA-PEGAutores:Antoni Camins, Calpena A.C., Cordeiro M.F., Davis B.M., Egea M.A., Espina M., Ettcheto M., García M.L., Guo L., Ravindran N., Sanchez-Lopez E., Silva A.M., Souto E.M.B.Fuentes:scopusPeripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer’s Disease
ArticleAbstract: There is growing evidence that obesity associated with type 2 diabetes mellitus (T2DM) and aging arePalabras claves:Alzheimer’s disease, APPswe/PS1dE9, DIABÉTES, high-fat diet, Memantine, obesityAutores:Antoni Camins, Auladell C., Busquets O., Cabrera H., Carro E., Casadesús G., Ettcheto M., Folch J., García M.L., Gómez-Mínguez Y., Sanchez-Lopez E., Vázquez-Carrera M., Zárate C.B.Fuentes:scopusThe implication of the brain insulin receptor in late onset Alzheimer’s disease dementia
ArticleAbstract: Alzheimer’s disease (AD) is progressive neurodegenerative disorder characterized by brain accumulatiPalabras claves:Alzheimer’s, amyloid, COGNITION, insulin receptor, Insulin Resistance, Tau, Type 2 DiabetesAutores:Antoni Camins, Auladell C., Busquets O., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Poor S.R., Sanchez-Lopez E., Verdaguer E., Zárate C.B.Fuentes:scopus